1. Home
  2. TRVI vs QQQX Comparison

TRVI vs QQQX Comparison

Compare TRVI & QQQX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$10.38

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

QQQX

Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

HOLD

Current Price

$27.42

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVI
QQQX
Founded
2011
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
TRVI
QQQX
Price
$10.38
$27.42
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
$20.38
N/A
AVG Volume (30 Days)
1.5M
127.6K
Earning Date
03-17-2026
01-01-0001
Dividend Yield
N/A
7.03%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.93
$20.27
52 Week High
$14.39
$25.99

Technical Indicators

Market Signals
Indicator
TRVI
QQQX
Relative Strength Index (RSI) 48.52 41.68
Support Level $10.41 $26.91
Resistance Level $11.93 $28.18
Average True Range (ATR) 0.70 0.40
MACD 0.07 -0.04
Stochastic Oscillator 57.59 31.94

Price Performance

Historical Comparison
TRVI
QQQX

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.

Share on Social Networks: